Yang S - Search Results

1

Discovery of α-Ketoamide inhibitors of SARS-CoV-2 main protease derived from quaternized P1 groups.

Huang Q, Quan B, Chen Y, Zhao X, Zhou Y, Huang C, Qiao J, Wang Y, Li Y, Yang S, Lei J, Li L. Huang Q, et al. Among authors: yang s. Bioorg Chem. 2024 Feb;143:107001. doi: 10.1016/j.bioorg.2023.107001. Epub 2023 Dec 6. Bioorg Chem. 2024. PMID: 38101266

2

An integrated scheme for feature selection and parameter setting in the support vector machine modeling and its application to the prediction of pharmacokinetic properties of drugs.

Yang SY, Huang Q, Li LL, Ma CY, Zhang H, Bai R, Teng QZ, Xiang ML, Wei YQ. Yang SY, et al. Artif Intell Med. 2009 Jun;46(2):155-63. doi: 10.1016/j.artmed.2008.07.001. Epub 2008 Aug 12. Artif Intell Med. 2009. PMID: 18701266

3

Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.

Wang HY, Cao ZX, Li LL, Jiang PD, Zhao YL, Luo SD, Yang L, Wei YQ, Yang SY. Wang HY, et al. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4972-7. doi: 10.1016/j.bmcl.2008.08.033. Epub 2008 Aug 14. Bioorg Med Chem Lett. 2008. PMID: 18762425

4

Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.

Xie QQ, Xie HZ, Ren JX, Li LL, Yang SY. Xie QQ, et al. J Mol Graph Model. 2009 Feb;27(6):751-8. doi: 10.1016/j.jmgm.2008.11.008. Epub 2008 Nov 27. J Mol Graph Model. 2009. PMID: 19138543

5

A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.

Wang HY, Li LL, Cao ZX, Luo SD, Wei YQ, Yang SY. Wang HY, et al. Chem Biol Drug Des. 2009 Jan;73(1):115-26. doi: 10.1111/j.1747-0285.2008.00751.x. Chem Biol Drug Des. 2009. PMID: 19152640

6

Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.

Xie HZ, Li LL, Ren JX, Zou J, Yang L, Wei YQ, Yang SY. Xie HZ, et al. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1944-9. doi: 10.1016/j.bmcl.2009.02.049. Epub 2009 Feb 20. Bioorg Med Chem Lett. 2009. PMID: 19254842

7

Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors.

Chen JJ, Liu TL, Yang LJ, Li LL, Wei YQ, Yang SY. Chen JJ, et al. Chem Pharm Bull (Tokyo). 2009 Jul;57(7):704-9. doi: 10.1248/cpb.57.704. Chem Pharm Bull (Tokyo). 2009. PMID: 19571415 Free article.

8

Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.

Ren JX, Li LL, Zou J, Yang L, Yang JL, Yang SY. Ren JX, et al. Eur J Med Chem. 2009 Nov;44(11):4259-65. doi: 10.1016/j.ejmech.2009.07.008. Epub 2009 Jul 16. Eur J Med Chem. 2009. PMID: 19640613

9

Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.

Yang LJ, Zou J, Xie HZ, Li LL, Wei YQ, Yang SY. Yang LJ, et al. PLoS One. 2009 Dec 24;4(12):e8470. doi: 10.1371/journal.pone.0008470. PLoS One. 2009. PMID: 20041122 Free PMC article.

10

PhDD: a new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility.

Huang Q, Li LL, Yang SY. Huang Q, et al. J Mol Graph Model. 2010 Jun;28(8):775-87. doi: 10.1016/j.jmgm.2010.02.002. Epub 2010 Feb 11. J Mol Graph Model. 2010. PMID: 20206562

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53,848 results

Search Page

Filters